4D Molecular Therapeutics, Inc. Operating Lease Right-of-Use Assets
4D Molecular Therapeutics, Inc. (FDMT) had Operating Lease Right-of-Use Assets of $16.55 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $16.55M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $17.36M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $18.14M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $18.91M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $16.55M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $17.36M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $18.14M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $18.91M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $19.65M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $20.37M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $21.07M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $21.76M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $10.69M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $11.12M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $11.54M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $11.95M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $12.35M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $12.70M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $13.09M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $13.46M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $13.82M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $14.19M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $14.56M 10-K · filed 2023-03-15 | |
| 2021-01-01 | $16.50M 10-K · filed 2023-03-15 | $16.54M 10-K · filed 2022-03-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |